Sept. 16, 2025
| Today’s news and insights for biopharma leaders
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.
|
Led by former founders of a biotech AstraZeneca acquired in 2023, AllRock Bio is starting out with a drug licensed from Sanofi that’ll be tested against pulmonary arterial hypertension.
|
UPDATED
HHS nominated five new members to ACIP ahead of a meeting Thursday and Friday that could prove an inflection point in HHS Secretary’s Kennedy’s efforts to overhaul U.S. vaccine policy.
|
Smarter cold chain design starts with thermal modeling—learn best practices here.
|
UPDATED
Versant Ventures co-led investments in AllRock and Dualitas Therapeutics, a developer of bispecific drugs for immune diseases that also launched on Tuesday.
|
Deep Dive
The AI models, which are built on massive datasets and can be adapted to multiple tasks, have become a part of medtech companies’ lexicon in the past few years.
|
The company’s new partnership with the "molecular glue” drug developer is broad, focused on immunology and could be worth up to $5.7 billion.
|
From Our Library
Trendline
Supported by Bio-Rad
|
Playbook
Custom content for PharmaForceIQ
|
Trendline
Supported by EVERSANA
|
| 
